CytomX Therapeutics, Inc.

CTMX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
CTMX Income Statement
CTMX Balance Sheet
CTMX Cash Flow
Congress Trading

Recent trades of CTMX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CTMX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CTMX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CTMX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CTMX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Protease-resistant systems for polypeptide display and methods of making and using thereof Nov. 12, 2024
  • Patent Title: Activatable cytokine constructs and related compositions and methods Sep. 17, 2024
  • Patent Title: Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof Jul. 30, 2024
  • Patent Title: Compositions and methods for conjugating activatable antibodies May. 28, 2024
  • Patent Title: Activatable antibodies that bind epidermal growth factor receptor and methods thereof Feb. 06, 2024
  • Patent Title: Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof Jan. 30, 2024
  • Patent Title: Compositions and methods for detecting protease activity in biological systems Jan. 09, 2024
  • Patent Title: Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof Jan. 02, 2024
  • Patent Title: Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof Nov. 14, 2023
  • Patent Title: Bispecific anti-cd3 antibodies, bispecific activatable anti-cd3 antibodies, and methods of using the same Oct. 31, 2023
  • Patent Title: Masked activatable interferon constructs Jun. 06, 2023
  • Patent Title: Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof Jan. 10, 2023
  • Patent Title: Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof Jan. 10, 2023
  • Patent Title: Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof Oct. 18, 2022
  • Patent Title: Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof Oct. 18, 2022
  • Patent Title: Activatable cytokine constructs and related compositions and methods Jun. 21, 2022
  • Patent Title: Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof Mar. 08, 2022
  • Patent Title: Anti-cd166 antibodies and uses thereof Jan. 11, 2022
  • Patent Title: Protease-resistant systems for polypeptide display and methods of making and using thereof Dec. 14, 2021
  • Patent Title: Method of treating or delaying progression of an epidermal growth factor receptor (egfr)-related disorder by administering activatable egfr-binding antibodies Nov. 23, 2021
  • Patent Title: Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof Nov. 16, 2021
  • Patent Title: Activatable anti-pdl1 antibodies, and methods of use thereof Nov. 09, 2021
  • Patent Title: Multispecific antibodies, multispecific activatable antibodies and methods of using the same Nov. 02, 2021
  • Patent Title: Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof Jun. 29, 2021
  • Patent Title: Compositions and methods for detecting protease activity in biological systems Jun. 15, 2021
  • Patent Title: Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof Jun. 08, 2021
  • Patent Title: Protease-resistant systems for polypeptide display and methods of making and using thereof Mar. 16, 2021
  • Patent Title: Activatable antibodies having non-binding steric moieties and methods of using the same Jan. 19, 2021
  • Patent Title: Methods of treatment using activatable anti-egfr antibodies Dec. 29, 2020
  • Patent Title: Therapeutic antibodies Oct. 13, 2020
  • Patent Title: Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof Aug. 18, 2020
  • Patent Title: Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof Jul. 14, 2020
  • Patent Title: Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof Jun. 02, 2020
  • Patent Title: Bispecific anti-cd3 antibodies, bispecific activatable anti-cd3 antibodies, and methods of using the same Jun. 02, 2020
  • Patent Title: Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof Mar. 03, 2020
  • Patent Title: Antibodies that bind activatable antibodies and methods of use thereof Feb. 25, 2020
  • Patent Title: Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor Jan. 14, 2020
  • Patent Title: Anti-pd1 antibodies, activatable anti-pd1 antibodies, and methods of use thereof Dec. 24, 2019
  • Patent Title: Cleavage-activatable interferon-alpha proprotein Dec. 24, 2019
  • Patent Title: Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of thereof Jul. 02, 2019
  • Patent Title: Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof May. 28, 2019
  • Patent Title: Compositions and methods for detecting protease activity in biological systems Apr. 16, 2019
  • Patent Title: Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof Mar. 19, 2019
  • Patent Title: Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof Jan. 15, 2019
  • Patent Title: Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof Nov. 27, 2018
  • Patent Title: Modified antibody containing the cleavable peptide with the amino acid sequence tgrgpswv Nov. 06, 2018
  • Patent Title: Anti-egfr activatable antibodies Aug. 28, 2018
  • Patent Title: Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof Feb. 13, 2018
  • Patent Title: Activatable antibodies having non-binding steric moieties and methods of using the same Jan. 02, 2018
  • Patent Title: Antibodies that bind activatable antibodies and methods of use thereof Aug. 22, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CTMX in WallStreetBets Daily Discussion

CTMX News

Recent insights relating to CTMX

CNBC Recommendations

Recent picks made for CTMX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CTMX

CTMX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CTMX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top